See more : Swancor Holding Co., LTD. (3708.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Q BioMed Inc. (QBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Q BioMed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SPI Energy Co., Ltd. (SPI) Income Statement Analysis – Financial Results
- Anadolu Efes Biracilik ve Malt Sanayii Anonim Sirketi (AEBZY) Income Statement Analysis – Financial Results
- Excellence Commercial Property & Facilities Management Group Limited (6989.HK) Income Statement Analysis – Financial Results
- Village Vanguard CO.,LTD. (2769.T) Income Statement Analysis – Financial Results
- LMF Acquisition Opportunities Inc. (LMAOW) Income Statement Analysis – Financial Results
Q BioMed Inc. (QBIO)
About Q BioMed Inc.
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.35K | 195.60K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 293.34K | 246.85K | 326.01K | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 | 38.05K | 0.00 |
| Gross Profit | -8.99K | -51.25K | -296.01K | -50.00K | 0.00 | 0.00 | 0.00 | 0.00 | -38.05K | 0.00 |
| Gross Profit Ratio | -3.16% | -26.20% | -986.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 125.38K | 1.07M | 1.88M | 3.54M | 3.24M | 3.10M | 1.31M | 598.00K | 0.00 | 0.00 |
| General & Administrative | 3.28M | 6.26M | 10.97M | 4.48M | 5.78M | 9.27M | 5.03M | 354.14K | 38.05K | 500.00 |
| Selling & Marketing | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.31M | 6.26M | 10.97M | 4.48M | 5.78M | 9.27M | 5.03M | 354.14K | 38.05K | 500.00 |
| Other Expenses | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.44M | 7.34M | 12.85M | 8.02M | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 500.00 |
| Cost & Expenses | 3.73M | 7.58M | 13.18M | 8.02M | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 500.00 |
| Interest Income | 0.00 | 506.92K | 296.22K | 1.46M | 0.00 | 138.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38M | 506.92K | 296.22K | 1.46M | 162.10K | 760.31K | 480.29K | 14.51K | 0.00 | 0.00 |
| Depreciation & Amortization | 50.00K | 50.00K | 50.00K | 50.00K | 9.02M | 12.37M | 6.35M | 952.14K | 38.05K | 0.00 |
| EBITDA | -617.63K | -7.68M | -13.15M | -7.97M | -89.00K | -1.41M | -344.72K | -119.97K | 0.00 | -500.00 |
| EBITDA Ratio | -217.21% | -3,751.88% | -43,651.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.45M | -7.39M | -13.15M | -8.02M | -9.02M | -12.37M | -6.35M | -952.14K | -38.05K | -500.00 |
| Operating Income Ratio | -1,211.74% | -3,777.44% | -43,818.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.39M | -851.99K | -346.78K | -2.26M | -251.10K | -2.17M | -825.00K | -134.48K | 0.00 | 0.00 |
| Income Before Tax | -2.05M | -8.24M | -13.49M | -10.28M | -9.27M | -14.54M | -7.17M | -1.09M | -38.05K | -500.00 |
| Income Before Tax Ratio | -721.67% | -4,213.02% | -44,973.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 506.92K | 296.22K | 1.46M | 251.10K | 760.18K | -5.87M | -937.63K | 0.00 | 0.00 |
| Net Income | -2.05M | -8.75M | -13.79M | -11.74M | -9.27M | -14.54M | -7.17M | -1.09M | -38.05K | -500.00 |
| Net Income Ratio | -721.67% | -4,472.19% | -45,961.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.08 | -0.33 | -0.62 | -0.78 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | 0.00 |
| EPS Diluted | -0.08 | -0.33 | -0.62 | -0.78 | -0.67 | -1.39 | -0.81 | -0.12 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 44.76M | 26.78M | 22.16M | 15.04M | 13.74M | 10.47M | 8.86M | 9.07M | 6.51M | 2.78M |
| Weighted Avg Shares Out (Dil) | 44.76M | 26.78M | 22.16M | 15.04M | 13.74M | 10.47M | 8.86M | 9.07M | 6.51M | 2.78M |
Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience
NEW YORK, May 20, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creating access for and selling pharmaceuticals, medical diagnostics...
Q BioMed announces up to $30M investment from insider, allowing it to advance company's growth plans
Q BioMed Inc (OTCQB:QBIO) has unveiled its largest single investment so far, with Aedesius Holdings Ltd (AedesiusOne), a privately held global disruption aggregator, investing up to $30 million in the company via a securities agreement. The biotech accelerator noted that AedesiusOne is...
Q BioMed touts development progress of coronavirus treatment MAN-19 and other therapies in letter to shareholders
Q BioMed Inc (OTCQB:QBIO) has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus (COVID-19). The company announced in March that Mannin would...
Q BioMed Updates Shareholders
NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Research Inc. (Mannin), is receiving up to CAD$1.7 million in research and...
Q BioMed has a winner in cancer bone pain drug Strontium89 and a deep pipeline of biomedical assets
Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Strontium89 for sale in all 50 US states What Q BioMed does: Q BioMed Inc...
US stocks mixed at open as traders look for direction
10.25am: Proactive North America headlines: Tartisan Nickel Corp (CSE:TN) (OTCMKTS:TTSRF) (FRA:8TA) poised for geophysical survey at flagship Kenbridge nickel-copper-cobalt project Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) says it received 'positive' results from its Maximum Tolerated Dosage study of AME-1 Medexus...
Q BioMed announces five year contract with the US Department of Defense and Veterans Affairs for its cancer bone pain drug
Q BioMed Inc (OTCQB:QBIO) has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiaries. The biotech has inked a deal...
Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment...
Source: https://incomestatements.info
Category: Stock Reports